Dashboard › Demo Universe › Halcyon Medical Devices

Halcyon Medical Devices · HLCN

DEMO DATAUNDERWRITING ASSUMPTIONHOLD
Five-minute case summary

Halcyon Medical Devices

DEMO DATAUNDERWRITING ASSUMPTION
HOLD
1
The opportunity
Demo purchase of $100M face of Senior Notes 5.90% at 96.5 (cash investment $97.0M): current yield 6.1%, yield to maturity 6.7%.
2
The question
Does a 6.7% yield on a rank-3 unsecured claim compensate for 0% probability-weighted default risk and 0% severe-case loss?
3
The thesis
Defensive, cash-generative credit with ample asset and enterprise-value coverage. The 2031 notes at a ~4-pt discount offer a mid-single-digit-plus yield with strong downside protection.
4
The risk (what causes loss)
  • Unsecured, rank 3: $400M of debt ranks ahead.
  • Weakest credit-score factor: Industry risk (8.0 of 10 points).
  • Reimbursement or tariff pressure
  • Product recall / litigation
5
The protection
  • Severe-case valuation recovery of 100% covers the 96.5 purchase price (principal protected).
  • Coverage of 5.69x EBITDA / interest; EBITDA can fall 82% before coverage reaches 1.0x.
  • Moderate leverage: net debt / EBITDA 2.0x.
  • Liquidity of $470M (52% of total debt).
6
The base case
Base case (55%): revenue 5.0% in FY2026E, EBITDA margin 24.0%; no default; IRR 7.1%, MOIC 1.21x vs 12% hurdle.
7
The downside
Downside (30%): EBITDA $288M at the trough, peak net leverage 1.8x, covenants hold; no default; IRR 3.8%. Severe (15%): no default, IRR -3.5%.
8
The recovery
If the company defaults, recovery value is $2.2B (going concern) in the severe case → 100% recovery (0% LGD) on the target tranche; downside 100%.
9
The decision
HOLD. HOLD (do not size yet): Base-case IRR clears hurdle (7.1% vs ≥ 12.0%); Expected-cash-flow IRR (probability-weighted) clears hurdle (4.6% vs ≥ 12.0%); Entry yield meets minimum (6.7% vs ≥ 9.0%).

Generated from the structured model (no free-text generation beyond the analyst’s thesis and risk lists). Hypothetical terms are underwriting assumptions; nothing here is a real transaction.